InMed Pharmaceuticals Regains Nasdaq Listing Compliance

InMed Pharmaceuticals Inc. has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company's share price closed at or above $1.00 for ten consecutive business days, satisfying the exchange's listing rule. This ensures InMed's continued listing status on The Nasdaq Capital Market.